The ACCC has granted authorisation to allow the members of both Medicines Australia (MA) and the Generic and Biosimilar Medicines Association (GBMA) to cooperate in relation to the supply of prescription-only medicines that are critical to patient health and devices or services that are supplied or administered with these medicines, if there are shortages resulting from the COVID-19 pandemic.
The application was lodged by MA on behalf of itself, its members and the GBMA, and its members, (together the MA/GBMA Working Group) and future members of the MA/GBMA Working Group.
The ACCC considers that the proposed conduct is likely to result in public benefits by allowing the MA/GBMA Working Group to work together and where necessary, with relevant Government agencies, to ensure supply of these essential medicines and devices.
The ACCC has decided to grant authorisation until 30 September 2021.
Authorisation is subject to conditions that allow the ACCC to monitor the authorised conduct. The conditions also require MA to advise government health agencies if MA/GBMA Working Group members intend to coordinate in relation to Government tenders for essential medicines and associated devices.
Further information about the ACCC’s final determination is available on the ACCC’s public register at: Medicines Australia.